학술논문
Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma
Document Type
article
Author
Xiaozhe Li; Xiuli Sun; Baijun Fang; Yun Leng; Fangfang Sun; Yaomei Wang; Qing Wang; Jie Jin; Min Yang; Bing Xu; Zhihong Fang; Lijuan Chen; Zhi Chen; Qimei Yang; Kejie Zhang; Yinhai Ye; Hui Geng; Zhiqiang Sun; Dan Hao; Hongming Huang; Xiaotao Wang; Hongmei Jing; Lan Ma; Xueyi Pan; Wenming Chen; Juan Li
Source
Thrombosis Journal, Vol 21, Iss 1, Pp 1-13 (2023)
Subject
Language
English
ISSN
1477-9560
Abstract
Abstract Background Individuals with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) are at risk of developing venous thromboembolism (VTE), a serious complication. There is no established clinical model for predicting VTE in the Chinese population. We develop a new risk assessment model (RAM) for IMiD-associated VTE in Chinese MM patients. Methods We retrospectively selected 1334 consecutive MM patients receiving IMiDs from 16 medical centers in China and classified them randomly into the derivation and validation cohorts. A multivariate Cox regression model was used for analysis. Results The overall incidence of IMiD-related VTE in Chinese MM patients was 6.1%. Independent predictive factors of VTE (diabetes, ECOG performance status, erythropoietin-stimulating agent use, dexamethasone use, and VTE history or family history of thrombosis) were identified and merged to develop the RAM. The model identified approximately 30% of the patients in each cohort at high risk for VTE. The hazard ratios (HRs) were 6.08 (P